Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 106, Issue 6, 2002, Pages 351-354

  Jiménez Jiménez, Félix Javier ^a,b   Zurdo, J M ^a   Hernanz, A ^b   Medina Acebron S ^b   De Bustos, F ^c   Barcenilla, B ^a   Sayed, Y ^a   Ayuso Peralta, L ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b Ciudad Sanitaria La Paz ^*  (Spain)

^c HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

Author keywords

Axonal damage; Cerebrospinal fluid; Multiple sclerosis; Tau protein

Indexed keywords

TAU PROTEIN;

ADULT; APOPTOSIS; ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DEMYELINATING DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; PROTEIN STABILITY; SYNAPTIC TRANSMISSION;

ADULT; AGE OF ONSET; AXONS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPINAL PUNCTURE; TAU PROTEINS; TIME FACTORS;

EID: 0036913313     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2002.01370.x     Document Type: Article

References (28)

1. Wynn DR, Rodríguez M, O'Fallon WM, Kurland LT. Update on the epidemiology of multiple sclerosis. Mayo Clin Proc 1989;64:808-17.
2. Allen I. Aetiological hypotheses for multiple sclerosis: evidence from human and experimental diseases. In: Matthews WB, Compston AV, Allen IV, Martyn CM, eds. Mcalpine's Multiple Sclerosis. Edinbourgh: Churchill Livingstone, 1991; 379-90.
3. Martyn C. The epidemiology of multiple sclerosis. In: Matthews WB, Compston AV, Allen IV, Martyn CM, eds. Mcalpine's Multiple Sclerosis. Edinbourgh: Churchill Livingstone, 1991; 3-40.
4. Poser CM. Multiple sclerosis, observations and reflections - A personal memoir. J Neurol Sci 1992;107:127-40.
5. Dudek I, Zagorski T, Liskiewicz J, Kedziora J, Chmielewski H. Effect of gamma radiation on selected indicators of oxygen metabolism in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 1992;26:34-9.
6. Langemann H, Kabiersch A, Newcombe J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 1992;32:248-52.
7. Toshniwal PK, Zarling EJ. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem Res 1992;17:205-7.
8. Newcombe J, Li H, Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathol Appl Neurobiol 1994;20:152-62.
9. Calabrese V, Raffaele R, Cosentino E, Rizza V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 1994;14:119-23.
10. Bongarzone ER, Pasquini JM, Soto EF. Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J Neurosci Res 1995;41:213-21.
11. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9.
12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö I. Axon transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
13. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet 1998;352:340-1.
14. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated spinal cord plaques. Brain 2000;123:308-17.
15. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-83.
16. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-8.
17. Alcázar A, Regidor I, Masjuán J, Salinas M, Alvarez-Cermeño JC. Axonal damage induced by cerebrospinal fluid from patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2000;104:58-67.
18. Delacourte A. Pathological tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration. Biomed Pharmacother 1994;48:287-95.
19. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidiereas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43:228-32.
20. Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): A blood-SSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:195-8.
21. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-31.
22. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid in patients with dementia of Alzheimer type. J Neurol Neurosurg Psychiatry 1995;59:280-3.
23. Moreu E, Molinero LM, Fernández E. R-Sigma. Base de Datos Bioestadística para un Ordenador Personal. Madrid: Horus Hardware, 1990.
24. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4.
25. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-9.
26. Martínez-Yelamos A, Saiz A, Sánchez-Valle R et al. 14-3-3 protein in the CSF as a prognostic marker in early multiple sclerosis. Neurology 2001;55:722-4.
27. Eder U, Leitner B, Kirchmair R et al. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm 1998;105:39-51.
28. de la Monte SM, Volicer L, Hauser SL, Wands JR. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1992;32:733-42.